Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser resurfacing may shield aging skin from cancer

NCT ID NCT06428721

Prevention Sponsor: Wright State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether a laser treatment called fractionated laser resurfacing (FLR) can protect the forearms of older adults from precancerous spots (actinic keratoses) and non-melanoma skin cancer. Participants are 60 or older with fair skin and at least five precancerous spots on each forearm. One forearm receives the laser treatment, while the other serves as a comparison. The study also explores whether skin photographs can predict where future spots or cancers will appear.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fractionated Laser Resurfacing (FLR) — a laser that creates tiny holes in the skin's surface to rejuvenate it.
What this could lead to
If it works, this could offer a way to prevent skin cancer in older adults without daily creams or frequent doctor visits.
What could go wrong
This is a small, early study with 80 people, so results may not apply to everyone. The laser procedure can cause temporary redness, swelling, or discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult Males and Females aged 60 and older * Have at least 5 AKs on each forearm/wrist, but no more than 10 to allow for easy monitoring * Skin type fair (Fitzpatrick I-II) * Females must be post-menopausal and not be on systemic hormone replacement therapy * Able to comprehend procedures and risks Exclusion Criteria: * More than 10 AKs on an extremity * AKs that are large (2-3+, hyperkeratotic grade 3 lesions) * AKs that are very thick (\>3 mm) * Medical history of diabetes * History of poor wound healing or scarring * Large tattoos that can interfere with study * Other serious health issues and other skin diseases that could interfere with the study * Recent (within 1 year) field therapies such as efudex cream or PDT to forearms/wrists. * Planning to leave region in next 5 years * Subjects with allergies to xylocaine will be excluded if they need this topical anesthetic.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Actinic keratoses are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

actinic keratosis skin carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Actinic keratoses Aging Non-melanoma skin cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Wright State Physicians

    RECRUITING

    Fairborn, Ohio, 45324, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.